3M Looking to Open Markets for Materials in Proteomics
3M is investigating ways to apply its materials technology to proteomics and other biotechnology applications, ProteoMonitor learned last week.
Although the company has not made any public announcement of its intentions, a senior scientist said 3M has been “exploring proteomics” and how to apply the company’s materials know-how to applications in the sector.
3M’s proprietary materials are currently employed in the capillary arrays used in Applied Biosystems’ 3700 series DNA sequencers. “We’re continuing to work both in genomics and proteomics,” the 3M scientist said.
WITA Proteomics to Analyze Proteins in Food for Nestlé
WITA Proteomics of Berlin has signed an agreement to provide protein analysis services for Swiss food giant Nestlé, WITA said last week.
Using its 2D gel electrophoresis and mass spectrometry proteomics platform, WITA will separate and identify proteins found in various food products.
WITA Proteomics will retain certain rights to use the proteins it identifies for future diagnostic and therapeutic use, whereas Nestlé will keep all rights for food applications and certain rights for therapeutic and cosmetic applications.
The companies said that proteomics could help to determine whether post-translational modifications produce proteins of differing nutritional value.
“The use of proteomics offers Nestlé a new tool for the continued development and manufacture of high-quality, value-added food products,” Andrea Pfeifer, head of Nestle’s research center, said in a statement.
ABI and Millipore Fund Proteomics at Univ. of Tokyo
The Japanese subsidiaries of Applied Biosystems and Millipore have funded a center for proteomics research in the Institute of Medical Science at the University of Tokyo, the companies said last week.
Although the amount of funding was undisclosed, the companies said the money would support the development of new techniques for protein expression profiling and the study of protein-protein interactions.
Toshiaki Isobe, a visiting professor at the university, will serve as the director of the center. ABI and Millipore agreed to fund the center for three years, with an option to extend the funding to five.
Pluvita Subscribes to AxCell Biosciences’ Database
Biotechnology company Pluvita has signed a three-year, non-exclusive deal for access to AxCell Biosciences’ ProChart database, which contains information on signal transduction pathways in the human proteome, AxCell said last week.
The database includes the map of the WW protein domain family, a human domain family involved in signal transduction. ProChart also includes protein pathway information from several other domain families, such as PDZ, SH2 and SH3.
Pluvita, a privately-held company based in Bethesda, Md., said it would use the database in a number of its research and drug discovery initiatives.
“We have a systems biology approach for discovering unique genes involved in pathogenesis,” said Pluvita CEO Gary Kurtzman. “Our discoveries will lead us to the identification of possible pathways, and in order to complete that you need to know what other proteins are involved. That’s what AxCell’s database will provide.”